News & Media | Iambic Therapeutics

NEWS & MEDIA

Read our recent announcements

Announcement

October 5, 2026

Iambic Submits IND for a Potentially Brain-Penetrant KIF18A Inhibitor IAM217, Its Second Wholly Owned AI-Discovered Candidate

Press

June 10, 2025

Iambic Named to CNBC’s 2025 Disruptor 50 List

Press

June 4, 2025

Iambic Completes Dose Escalation in Ongoing Phase 1/1B Study of Lead Program IAM1363, a Small Molecule Inhibitor of Wild-Type and Oncogenic HER2 Mutant Proteins

Press

May 28, 2025

Iambic to Participate in June Investor Conferences

Presentation

May 13, 2025

Panel presentation at the Bank of America Healthcare Conference

Press

May 5, 2025

Iambic Announces Enchant v2, its Next Generation AI Model for Predicting the Clinical Viability of Drug Discovery Programs

Publication

May 5, 2025

Enchant v2: Pushing the Boundaries of Predictive Drug Discovery

Publication

April 29, 2025

A Novel KIF18A Inhibitor for Targeting Chromosomal Instability in Cancer (AACR 2025 Poster)

Presentation

April 29, 2025

Poster presented at the 2025 American Association of Cancer Research Annual Meeting

Presentation

April 16, 2025

Presentation by CTO Fred Manby, PhD, at Drug Discovery Chemistry

September 21, 2026

Iambic Launches Enchant v3 – Molecular Superintelligence Designed to Advance End-to-End Drug Discovery & Development

September 21, 2026

AbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug Discovery

Bayer and Iambic collaborate to advance drug discovery with AI

Iambic Named to CNBC Disruptor 50 for Second Consecutive Year

Iambic to participate in upcoming investor conferences

Iambic to Participate in April Investor Conferences

December 7, 2025

Scaling Multi-Modal and Multi-Task Transformers for Small Molecule Drug Discovery

December 3, 2025

San Diego NeuralPLexer3: Accurate Biomolecular Complex Structure Prediction with Flow Models

October 19, 2025

A Phase 1/1b Study of IAM1363, a selective and brain penetrant HER2 inhibitor in participants (pts) with advanced cancers harboring HER2 alterations

September 9, 2025

IAM1363 is a Potent, Selective, and Irreversible HER2 and Pan-HER2 Mutant Small Molecule Inhibitor for the Treatment of HER2-Driven NSCLC

Enchant v2: Pushing the Boundaries of Predictive Drug Discovery

A Novel KIF18A Inhibitor for Targeting Chromosomal Instability in Cancer (AACR 2025 Poster)

December 16, 2024

NeuralPLexer3: Accurate Biomolecular Complex Structure Prediction with Flow Models

October 29, 2024

Enchant whitepaper: Breaking the data wall between lab and clinic

Multi-Modal and Multi-Task Transformer for Small Molecule Drug Discovery

January 13, 2026

JPM Healthcare Conference 2026 Company Presentation

October 30, 2025

Promise & Reality: Decoding AI’s Impact On Drug Development

October 28, 2025

From Models to Medicines: Delivering on the Promise of AI-Driven Drug Discovery

September 23, 2025

Enchant: A Multi-Modal Transformer Model to Break Down the Data Wall between Preclinical and Clinical Research and Development

September 22, 2025

Leveraging AI/ML to Engineer Next-Generation HER2 Inhibitors with Enhanced Selectivity and Brain Penetrance

September 10, 2025

Predictive Drug Discovery with Enchant v2

August 18, 2025

Iambic will present new preclinical NSCLC data for IAM1363, a potent Type II HER2 inhibitor, at #WCLC25

August 11, 2025

Fireside chat at the KeyBanc Capital Markets Technology Leadership Forum

Video: Iambic CEO Tom Miller Interview at the NASDAQ MarketSite

For media requests

Contact our communications team at media@iambic.ai